Press Releases

LBB Specialties, a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will distribute Clariant's pharmaceutical-grade high-functional excipients – including their polyethylene glycols (PEGs) and VitiPure® portfolio – for ophthalmic applications in the North American Life Sciences market. This pa

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, and a company of Danaher Corporation, launches the Cydem VT Automated Clone Screening System, a revolutionary high-throughput microbioreactor platform for automated top clone screening. The new Cydem VT System significantly reduces time to market for biologic drug discovery and monoclonal antibody-based therapeutics, by slashing manual laboratory steps in Cell Line Development up to 90% in a sing

VivaVision Biotech, a clinical-stage, privately held biotechnology company focused on developing treatments for ocular diseases, today announced positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201, a potent non-steroidal dual JAK1/TYK2 immunomodulator for the treatment of post-operative inflammation following cataract surgery. The multicenter, randomized, double-masked, vehicle-controlled study enrolled 91 subjects who underwent routine unilateral cataract

Renalys Pharma, Inc., a late-stage clinical biopharmaceutical company announces that sparsentan, in-licensed from Travere Therapeutics, Inc. and currently in phase III clinical trials in Japan, has received Orphan Drug Designation from the Japanese Ministry of Health, Labour and Welfare for the indication of primary IgA nephropathy as of November 27, 2024. Orphan disease drugs are designated by the Minister of Health, Labour and Welfare for conditions with fewer than 50,000 eligible

Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI®" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia (early AD). LEQEMBI selectively binds to soluble Aβ aggregates (prot

Dr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck Sharp and Dohme LLC in the U.S. market. The product will be marketed by Dr. Reddy's. We are pleased to advance our growth with the launch of a limited-competition product. With our continuous focus on niche opportunities, we are proud to be the second generic to r

Nexus Pharmaceuticals, LLC announces the U.S. Food and Drug Administration (FDA) approval of Methylene Blue Injection, USP. Methylene Blue is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia. We are pleased to strengthen the supply of an AP-rated and TIAA compliant Methylene Blue Injection,” says Sridhar Desikan, Chief Scientific Officer at Nexus Pharmaceuticals. “The addition of Methylene Blue to our portfolio further emphasizes Nexus&rsq

Shuttle Pharmaceuticals Holdings, Inc. a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today first patient enrollment and dosing at the UVA Cancer Center in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. UVA is one of six cancer centers conducting the clinical trials. Shuttle Pharma previously announced the dosing of patients a

Eisai Co., Ltd. and Biogen Japan Ltd. announced today that Eisai has entered into a research collaboration agreement with the National Center of Neurology and Psychiatry (Location: Tokyo, “NCNP”) to conduct apolipoprotein E (APOE) genetic testing in the dementia research and development program, “Development and Analysis of a National Clinical Registry of Disease-Modifying Therapies for Alzheimer’s Disease” (“AD-DMT Registry”). The research will be im

GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have received IND clearance for Phase I clinical trial of 'GC1130A' in the US, Korea, and Japan and are currently conducting multi-national clinical trial. Through this Phase I clinical trial, they plan to evaluate the safety, toler